TV News LIES

Thursday, Sep 21st

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Aaron Hernandez Found to Have Severe C.T.E.

Aaron Hernandez found to have severe CTE Aaron Hernandez, the former New England Patriots tight end who committed suicide in April while serving...

ObamaCare enrollment groups learn extent of Trump cuts

Trump slashes ACA navigator funds by 85% State and local groups now know how much funding they'll have to help enroll people in...

Livid Jimmy Kimmel Turns Up The Heat On Sen. Bill Cassidy For Second Night

Jimmy KimmelFor the second night in a row Wednesday, late-night talk show host Jimmy Kimmel raged against...

CDC awards $28.6 million to states to fight opioid epidemic

opoiod epedomic in USThe Centers for Disease Control and Prevention announced on Tuesday it is awarding more than $28.6...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!